and
Empire Genomics
announced the formation of a strategic alliance.
ICON and Empire Genomics will partner to develop a service portfolio tailored to the development of personalized medicines. The partnership combines Empire Genomics’ expertise in pharmacogenomics, computational modeling of disease state, drug disposition and drug targets with ICON’s expertise in translational medicine, clinical trial design, and biomarkers. The combined service offering will enable the identification of responder target populations, permit the stratification of patients through the development and use of companion diagnostics and will streamline drug development programs through the generation and analysis of relevant data obtained in the pre-clinical and early stage clinical setting.
“We look to partner with companies, scientists, and research institutions that complement our corporate strategies and experience, and this collaboration gives us the opportunity to work with industry leading clinical units, translational medicine expertise, and the broader ICON full-service offering,” commented Anthony Johnson, Chief Executive Officer, Empire Genomics.
“Genomics plays an integral role in personalized medicine, and through our collaboration with Empire Genomics, we can now offer sponsors integrated personalized medicine services,” commented Dr. Cyril Clarke, Vice President Translational Medicine, ICON Development Solutions. “We believe that this partnership will help sponsors to speed development by enhancing target population identification to ultimately produce safer, more effective medicines.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.